Yin F, Liu X, He D, Li S, Feng X, Shi Y
Clin Transl Sci. 2025; 18(3):e70198.
PMID: 40065597
PMC: 11893725.
DOI: 10.1111/cts.70198.
Yan J, Nie M, Zhang H, Liu Y, Tang F
World J Gastroenterol. 2025; 31(9):100607.
PMID: 40061596
PMC: 11886040.
DOI: 10.3748/wjg.v31.i9.100607.
Hassan S, Perry C, Carey P, Colohan D, Eltaher M, Dawoud N
Crohns Colitis 360. 2025; 7(1):otae080.
PMID: 39867688
PMC: 11759274.
DOI: 10.1093/crocol/otae080.
Fabisiak A, Caban M, Dudek P, Strigac A, Malecka-Wojciesko E, Talar-Wojnarowska R
Therap Adv Gastroenterol. 2025; 18:17562848241309871.
PMID: 39758970
PMC: 11694300.
DOI: 10.1177/17562848241309871.
Jin X, Sun K, Wang L, Shen H, Ma D, Shen T
Therap Adv Gastroenterol. 2025; 18:17562848241307598.
PMID: 39758966
PMC: 11696958.
DOI: 10.1177/17562848241307598.
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.
Bertin L, Crepaldi M, Zanconato M, Lorenzon G, Maniero D, de Barba C
Clin Exp Gastroenterol. 2024; 17:261-315.
PMID: 39403342
PMC: 11472755.
DOI: 10.2147/CEG.S434014.
Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease.
Yeshi K, Jamtsho T, Wangchuk P
Molecules. 2024; 29(16).
PMID: 39203033
PMC: 11357616.
DOI: 10.3390/molecules29163954.
Combination treatment of inflammatory bowel disease: Present status and future perspectives.
Triantafillidis J, Zografos C, Konstadoulakis M, Papalois A
World J Gastroenterol. 2024; 30(15):2068-2080.
PMID: 38681984
PMC: 11045479.
DOI: 10.3748/wjg.v30.i15.2068.
Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.
Wang J, Kang G, Lu H, de Marco A, Yuan H, Feng Z
Clin Transl Med. 2024; 14(3):e1636.
PMID: 38533646
PMC: 10966562.
DOI: 10.1002/ctm2.1636.
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.
Wetwittayakhlang P, Lakatos P
J Can Assoc Gastroenterol. 2024; 7(1):22-29.
PMID: 38314172
PMC: 10836999.
DOI: 10.1093/jcag/gwad032.
Transcutaneous auricular vagus nerve stimulation attenuates inflammatory bowel disease in children: a proof-of-concept clinical trial.
Sahn B, Pascuma K, Kohn N, Tracey K, Markowitz J
Bioelectron Med. 2023; 9(1):23.
PMID: 37849000
PMC: 10583463.
DOI: 10.1186/s42234-023-00124-3.
Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease.
Solitano V, Ma C, Hanzel J, Panaccione R, Feagan B, Jairath V
Gastroenterol Hepatol (N Y). 2023; 19(5):251-263.
PMID: 37799456
PMC: 10548249.
The Future of Advanced Therapies for Pediatric Crohn's Disease.
Gallagher J, Rosh J, Sahn B
Paediatr Drugs. 2023; 25(6):621-633.
PMID: 37612580
DOI: 10.1007/s40272-023-00590-x.
Novel Hydrogen Sulfide Hybrid Derivatives of Keap1-Nrf2 Protein-Protein Interaction Inhibitor Alleviate Inflammation and Oxidative Stress in Acute Experimental Colitis.
Zhang X, Cui K, Wang X, Tong Y, Liu C, Zhu Y
Antioxidants (Basel). 2023; 12(5).
PMID: 37237928
PMC: 10215391.
DOI: 10.3390/antiox12051062.
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.
McCormack M, Wahedna N, Aldulaimi D, Hawker P
World J Clin Cases. 2023; 11(12):2621-2630.
PMID: 37214562
PMC: 10198105.
DOI: 10.12998/wjcc.v11.i12.2621.
Dual Biologic Therapy in a Patient With Niemann-Pick Type C and Crohn Disease: A Case Report and Literature Review.
Hudson A, Almeida P, Huynh H
JPGN Rep. 2023; 3(3):e225.
PMID: 37168644
PMC: 10158355.
DOI: 10.1097/PG9.0000000000000225.
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies.
Cheah E, Huang J
World J Gastroenterol. 2023; 29(10):1539-1550.
PMID: 36970587
PMC: 10037250.
DOI: 10.3748/wjg.v29.i10.1539.
Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review.
State M, Negreanu L
Biomedicines. 2023; 11(2).
PMID: 36831079
PMC: 9953124.
DOI: 10.3390/biomedicines11020544.
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
Berinstein E, Sheehan J, Jacob J, Steiner C, Stidham R, Shannon C
Dig Dis Sci. 2023; 68(6):2604-2623.
PMID: 36807832
PMC: 9942632.
DOI: 10.1007/s10620-023-07837-0.
Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease.
Ahmed W
Crohns Colitis 360. 2023; 4(1):otac005.
PMID: 36777549
PMC: 9802154.
DOI: 10.1093/crocol/otac005.
